Journal articles: 'Antibody treatment'

1

Sasaki, Shigeru, Yasuhisa Shinomura, and Kozo Imai. "Antibody treatment." Drug Delivery System 30, no. 1 (2015): 16–24. http://dx.doi.org/10.2745/dds.30.16.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Jolobe, O. M. "Monoclonal antibody treatment." BMJ 340, apr01 2 (April 1, 2010): c1850. http://dx.doi.org/10.1136/bmj.c1850.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Litzman, Jiří. "Treatment of antibody immunodeficiency." Vnitřní lékařství 65, no. 2 (February 1, 2019): 126–30. http://dx.doi.org/10.36290/vnl.2019.025.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Espinoza, LR. "Antiphospholipid Antibody Syndrome: Treatment." Lupus 5, no. 5 (October 1996): 456–57. http://dx.doi.org/10.1177/096120339600500525.

Full text

Abstract:

Of the many clinical manifestations seen in the antiphospholipid antibody syndrome (APAS), two deserve major therapeutic consideration: recurrent fetal loss and vascular thromboses. Treatment of these two major complications remain empirical, although recent studies appear to indicate the beneficial use of multiple therapeutic options including low dose aspirin, alone or in combination with a moderate amount of prednisone, heparin and intravenous gammaglobulin for the prevention of fetal loss, and longterm anticoagulation with maintenance of an international normalized ratio (INR) of 3 to 4 as an effective measure in the prevention of vascular thrombosis. The use of interleukin-3 in animal models of the syndrome has been shown to be effective in the prevention of fetal loss, and this therapeutic modality appears promising, particularly because of its recognized low frequency of side effects in therapeutic trials in humans.

APA, Harvard, Vancouver, ISO, and other styles

5

Mehdi, Ali A., Imad Uthman, and Munther Khamashta. "Treatment of antiphospholipid antibody syndrome." International Journal of Clinical Rheumatology 5, no. 2 (April 2010): 241–54. http://dx.doi.org/10.2217/ijr.10.8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Gibbons, W. "Antibody Treatment Joins AIDS Battle." Science News 139, no. 4 (January 26, 1991): 55. http://dx.doi.org/10.2307/3975553.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Liddle, Rachel. "Antibody treatment for ovarian cancer." Lancet Oncology 8, no. 8 (August 2007): 676. http://dx.doi.org/10.1016/s1470-2045(07)70229-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Vexler, Vladimir, and Jacky Woo. "Antibody treatment of ulcerative colitis." Drug Discovery Today: Therapeutic Strategies 3, no. 3 (September 2006): 353–60. http://dx.doi.org/10.1016/j.ddstr.2006.07.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Wahl, Denis, and Veronique Regnault. "Treatment of Antiphospholipid Antibody Syndrome." JAMA 296, no. 1 (July 5, 2006): 42. http://dx.doi.org/10.1001/jama.296.1.42.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Gardulf, Ann. "Immunoglobulin Treatment for Primary Antibody Deficiencies." BioDrugs 21, no. 2 (2007): 105–16. http://dx.doi.org/10.2165/00063030-200721020-00005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Carter, Thomas, Paul Mulholland, and Kerry Chester. "Antibody-targeted nanoparticles for cancer treatment." Immunotherapy 8, no. 8 (July 2016): 941–58. http://dx.doi.org/10.2217/imt.16.11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Stronkhorst, A., G. N. J. Tytgat, and S. J. H. Van Deventer. "CD4 Antibody Treatment in Crohn's Disease." Scandinavian Journal of Gastroenterology 27, sup194 (January 1992): 61–65. http://dx.doi.org/10.3109/00365529209096029.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Slomski, Anita. "Monoclonal Antibody Overcomes Migraine Treatment Failure." JAMA 328, no. 8 (August 23, 2022): 700. http://dx.doi.org/10.1001/jama.2022.13588.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Gao, Jie, Huaiwen Chen, Hao Song, Xiao Su, Fangfang Niu, Wei Li, Bohua Li, Jianxin Dai, Hao Wang, and Yajun Guo. "Antibody-Targeted Immunoliposomes for Cancer Treatment." Mini-Reviews in Medicinal Chemistry 13, no. 14 (December 31, 2013): 2026–35. http://dx.doi.org/10.2174/1389557513666131119202717.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Sinclair, Leslie. "Antibody Shows Promise As Alzheimer’s Treatment." Psychiatric News 47, no. 11 (June 2012): 23a. http://dx.doi.org/10.1176/pn.47.11.psychnews_47_11_23-a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Popova, E. V. "MONOCLONAL ANTIBODY FOR MULTIPLE SCLEROSIS TREATMENT." Medical Council, no. 10 (January 1, 2017): 65–68. http://dx.doi.org/10.21518/2079-701x-2017-10-65-68.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Badger, Christopher C., Claudio Anasetti, Jeff Davis, and Irwin D. Bernstein. "Treatment of Malignancy with Unmodified Antibody." Pathology and Immunopathology Research 6, no. 5-6 (1987): 419–34. http://dx.doi.org/10.1159/000157067.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

PULLYBLANK, A. M., and J. R. T. MONSON. "Monoclonal antibody treatment of colorectal cancer." BJS 84, no. 11 (November 1997): 1511–17. http://dx.doi.org/10.1111/j.1365-2168.1997.00560.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Lambert, John M., and Anna Berkenblit. "Antibody–Drug Conjugates for Cancer Treatment." Annual Review of Medicine 69, no. 1 (January 29, 2018): 191–207. http://dx.doi.org/10.1146/annurev-med-061516-121357.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Gould, Paula. "Monoclonal antibody aids colorectal-cancer treatment." Lancet Oncology 7, no. 5 (May 2006): 370. http://dx.doi.org/10.1016/s1470-2045(06)70681-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Sullivan, Timothy J., David Grimes, and Ian Bunce. "Monoclonal Antibody Treatment of Orbital Lymphoma." Ophthalmic Plastic & Reconstructive Surgery 20, no. 2 (March 2004): 103–6. http://dx.doi.org/10.1097/01.iop.0000115594.98470.ac.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Nicolas, J. F., N. Chamchick, J. Thivolet, J. Wijdenes, P. Morel, and J. P. Revillard. "CD4 antibody treatment of severe psoriasis." Lancet 338, no. 8762 (August 1991): 321. http://dx.doi.org/10.1016/0140-6736(91)90465-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Walko, Christine M., and Howard (Jack) West. "Antibody Drug Conjugates for Cancer Treatment." JAMA Oncology 5, no. 11 (November 1, 2019): 1648. http://dx.doi.org/10.1001/jamaoncol.2019.3552.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Baldwin, R. W., and V. S. Byers. "Monoclonal antibody immunoconjugates for cancer treatment." Current Opinion in Immunology 1, no. 5 (June 1989): 891–94. http://dx.doi.org/10.1016/0952-7915(89)90066-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Wu, Christopher, and Kenneth Kalunian. "Treatment of the antiphospholipid antibody syndrome." Current Rheumatology Reports 6, no. 6 (December 2004): 463–68. http://dx.doi.org/10.1007/s11926-004-0026-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Pullyblank, A. M., and J. R. T. Monson. "Monoclonal antibody treatment of colorectal cancer." British Journal of Surgery 84, no. 11 (November 1997): 1511–17. http://dx.doi.org/10.1002/bjs.1800841106.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Lim, Wendy, Mark Crowther, and John Eikelboom. "Treatment of Antiphospholipid Antibody Syndrome—Reply." JAMA 296, no. 1 (July 5, 2006): 42. http://dx.doi.org/10.1001/jama.296.1.43-a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Maarschalk-Ellerbroek, L. J., I. M. Hoepelman, and P. M. Ellerbroek. "Immunoglobulin treatment in primary antibody deficiency." International Journal of Antimicrobial Agents 37, no. 5 (May 2011): 396–404. http://dx.doi.org/10.1016/j.ijantimicag.2010.11.027.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Panda, Manasi. "Rabies-Monoclonal Antibody - A Perspective." Journal of Communicable Diseases 54, no. 03 (September 30, 2022): 22–26. http://dx.doi.org/10.24321/0019.5138.202285.

Full text

Abstract:

Rabies is an acute viral zoonotic disease that affects the central nervous system (CNS) of all warm-blooded animals, including mammals. Research studies and experience from across the world have demonstrated that appropriate administration of a combination of (a) local wound treatment, (b) anti-rabies vaccination and (c) passive immunization have proved to be quite effective in preventing the occurrence of rabies. As far as passive immunization is concerned, polyclonal plasma-derived rabies immunoglobulins (RIG) pose a number of limitations with scarce supply, high cost, etc. amongst many others. On the contrary Rabies Monoclonal Antibodies (R-mAb) are much cheaper, permit longer-term storage, etc. and hence could offer a more standardized, accessible, affordable and equally efficacious and safer alternative to RIG. Accordingly, this article has tried to throw light on the transition from RIG to monoclonal antibody-based Post Exposure Prophylaxis (PEP) which has been recommended by the WHO strongly. The advantages, limitations and future scope of R-mAb have been discussed at length to give a comprehensive idea about this novel invention in the field of medicine.

APA, Harvard, Vancouver, ISO, and other styles

30

Chiu, Daniel, John Rhee, and L. Nicolas Gonzalez Castro. "Diagnosis and Treatment of Paraneoplastic Neurologic Syndromes." Antibodies 12, no. 3 (July 31, 2023): 50. http://dx.doi.org/10.3390/antib12030050.

Full text

Abstract:

Paraneoplastic antibody syndromes result from the anti-tumor antibody response against normal antigens ectopically expressed by tumor cells. Although this antibody response plays an important role in helping clear a nascent or established tumor, the engagement of antigens expressed in healthy tissues can lead to complex clinical syndromes with challenging diagnosis and management. The majority of known paraneoplastic antibody syndromes have been found to affect the central and peripheral nervous system. The present review provides an update on the pathophysiology of paraneoplastic neurologic syndromes, as well as recommendations for their diagnosis and treatment.

APA, Harvard, Vancouver, ISO, and other styles

31

Yano, Yusuke, Nobuhito Hamano, Kenshin Haruta, Tomomi Kobayashi, Masahiro Sato, Yamato Kikkawa, Yoko Endo-Takahashi, et al. "Development of an Antibody Delivery Method for Cancer Treatment by Combining Ultrasound with Therapeutic Antibody-Modified Nanobubbles Using Fc-Binding Polypeptide." Pharmaceutics 15, no. 1 (December 30, 2022): 130. http://dx.doi.org/10.3390/pharmaceutics15010130.

Full text

Abstract:

A key challenge in treating solid tumors is that the tumor microenvironment often inhibits the penetration of therapeutic antibodies into the tumor, leading to reduced therapeutic efficiency. It has been reported that the combination of ultrasound-responsive micro/nanobubble and therapeutic ultrasound (TUS) enhances the tissue permeability and increases the efficiency of delivery of macromolecular drugs to target tissues. In this study, to facilitate efficient therapeutic antibody delivery to tumors using this combination system, we developed therapeutic antibody-modified nanobubble (NBs) using an Fc-binding polypeptide that can quickly load antibodies to nanocarriers; since the polypeptide was derived from Protein G. TUS exposure to this Herceptin®-modified NBs (Her-NBs) was followed by evaluation of the antibody’s own ADCC activity, resulting the retained activity. Moreover, the utility of combining therapeutic antibody-modified NBs and TUS exposure as an antibody delivery system for cancer therapy was assessed in vivo. The Her-NBs + TUS group had a higher inhibitory effect than the Herceptin and Her-NBs groups. Overall, these results suggest that the combination of therapeutic antibody-modified NBs and TUS exposure can enable efficient antibody drug delivery to tumors, while retaining the original antibody activity. Hence, this system has the potential to maximize the therapeutic effects in antibody therapy for solid cancers.

APA, Harvard, Vancouver, ISO, and other styles

32

Hosoya, Hitomi, and Surbhi Sidana. "Antibody-Based Treatment Approaches in Multiple Myeloma." Current Hematologic Malignancy Reports 16, no. 2 (March 17, 2021): 183–91. http://dx.doi.org/10.1007/s11899-021-00624-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Gao, Jie, Si-Shen Feng, and Yajun Guo. "Antibody engineering promotes nanomedicine for cancer treatment." Nanomedicine 5, no. 8 (October 2010): 1141–45. http://dx.doi.org/10.2217/nnm.10.94.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Scherrmann, Jean-Michel. "Antibody Treatment of Toxin Poisoning Recent Advances." Journal of Toxicology: Clinical Toxicology 32, no. 4 (January 1994): 363–75. http://dx.doi.org/10.3109/15563659409011037.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

White, Christine A., Robin L. Weaver, and Antonio J. Grillo-López. "Antibody-Targeted Immunotherapy for Treatment of Malignancy." Annual Review of Medicine 52, no. 1 (February 2001): 125–45. http://dx.doi.org/10.1146/annurev.med.52.1.125.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Pietersz, Geoffrey A., and Ian F. C. McKenzie. "Antibody Conjugates for the Treatment of Cancer." Immunological Reviews 129, no. 1 (October 1992): 57–80. http://dx.doi.org/10.1111/j.1600-065x.1992.tb01419.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Makawita, Shalini, and Funda Meric-Bernstam. "Antibody-Drug Conjugates: Patient and Treatment Selection." American Society of Clinical Oncology Educational Book, no. 40 (May 2020): 105–14. http://dx.doi.org/10.1200/edbk_280775.

Full text

Abstract:

Antibody-drug conjugates (ADCs) are a promising drug platform designed to enhance the therapeutic index and minimize the toxicity of anticancer agents. ADCs have experienced substantial progress and technological growth over the past decades; however, several challenges to patient selection and treatment remain. Methods to optimally capture all patients who may benefit from a particular ADC are still largely unknown. Although target antigen expression remains a biomarker for patient selection, the impact of intratumor heterogeneity on antigen expression, as well as the dynamic changes in expression with treatment and disease progression, are important considerations in patient selection. Better understanding of these factors, as well as minimum levels of target antigen expression required to achieve therapeutic efficacy, will enable further optimization of selection strategies. Other important considerations include understanding mechanisms of primary and acquired resistance to ADCs. Ongoing efforts in the design of its constituent parts to possess the intrinsic ability to overcome these mechanisms, including use of the “bystander effect” to enhance efficacy in heterogeneous or low target antigen-expressing tumors, as well as modulation of the chemical and immunophenotypic properties of antibodies and linker molecules to improve payload sensitivity and therapeutic efficacy, are under way. These strategies may also lead to improved safety profiles. Similarly, combination strategies using ADCs with other cytotoxic or immunomodulatory agents are also under development. Great strides have been made in ADC technology. With further refinements, this therapeutic modality has the potential to make an important clinical impact on a wider range of tumor types.

APA, Harvard, Vancouver, ISO, and other styles

38

van Deventer, S. J. H. "Anti-TNF antibody treatment of Crohn's disease." Annals of the Rheumatic Diseases 58, Supplement 1 (November 1, 1999): i114—i120. http://dx.doi.org/10.1136/ard.58.2008.i114.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Sattui, Sebastian E., and Robert F. Spiera. "Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis." Rheumatic Disease Clinics of North America 45, no. 3 (August 2019): 379–98. http://dx.doi.org/10.1016/j.rdc.2019.04.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Gilbert, EdwardM, JohnB O'Connell, M. Elizabeth Hammond, DaleG Renlund, FredrickS Watson, and MichaelR Bristow. "TREATMENT OF MYOCARDITIS WITH OKT3 MONOCLONAL ANTIBODY." Lancet 331, no. 8588 (April 1988): 759. http://dx.doi.org/10.1016/s0140-6736(88)91555-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

SKERRETT, S. "Antibody treatment of lower respiratory tract infections1." Seminars in Respiratory Infections 16, no. 1 (March 2001): 67–75. http://dx.doi.org/10.1053/srin.2001.22730.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Singh, Neeraj, John Pirsch, and Millie Samaniego. "Antibody-mediated rejection: treatment alternatives and outcomes." Transplantation Reviews 23, no. 1 (January 2009): 34–46. http://dx.doi.org/10.1016/j.trre.2008.08.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Ribas, Antoni, John M. Kirkwood, and Keith T. Flaherty. "Anti-PD-1 antibody treatment for melanoma." Lancet Oncology 19, no. 5 (May 2018): e219. http://dx.doi.org/10.1016/s1470-2045(18)30202-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Cornely, O. A., C. N. Heidecke, and M. Karthaus. "Opportunistic infections (OI) following monoclonal antibody treatment." Journal of Clinical Oncology 23, no. 16_suppl (June 2005): 2562. http://dx.doi.org/10.1200/jco.2005.23.16_suppl.2562.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Mulford, Deborah A., and Joseph G. Jurcic. "Antibody-based treatment of acute myeloid leukaemia." Expert Opinion on Biological Therapy 4, no. 1 (January 2004): 95–105. http://dx.doi.org/10.1517/14712598.4.1.95.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Garfin, Phillip M., and Eric J. Feldman. "Antibody-Based Treatment of Acute Myeloid Leukemia." Current Hematologic Malignancy Reports 11, no. 6 (October 12, 2016): 545–52. http://dx.doi.org/10.1007/s11899-016-0349-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Bosch, Xavier, Antonio Guilabert, Gerard Espinosa, and Eduard Mirapeix. "Treatment of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis." JAMA 298, no. 6 (August 8, 2007): 655. http://dx.doi.org/10.1001/jama.298.6.655.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Lown, John. "Enzyme treatment of platelets for antibody detection." Transfusion 43, no. 6 (May 21, 2003): 835. http://dx.doi.org/10.1046/j.1537-2995.2003.00415.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Ross, Ryan D., Lindsey H. Edwards, Alvin S. Acerbo, Michael S. Ominsky, Amarjit S. Virdi, Kotaro Sena, Lisa M. Miller, and D. Rick Sumner. "Bone Matrix Quality After Sclerostin Antibody Treatment." Journal of Bone and Mineral Research 29, no. 7 (June 25, 2014): 1597–607. http://dx.doi.org/10.1002/jbmr.2188.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Han, Yizhao, Zhuojun Liu, Jia Liu, Weiqi Yan, Yuanshi Xia, Shuhua Yue, and Jian Yu. "Antibody-Based Immunotherapeutic Strategies for the Treatment of Hematological Malignancies." BioMed Research International 2020 (September 18, 2020): 1–8. http://dx.doi.org/10.1155/2020/4956946.

Full text

Abstract:

As the most common type of cancer in the world, hematological malignancies (HM) account for 10% of all annual cancer deaths and have attracted more attention. Conventional treatments, such as chemotherapy, radiotherapy, and hematopoietic stem cell transplantation (HSCT), could relieve patients suffering HM. However, serious side effects and high costs bring patients both physical complaints and mental pressure. Recently, compared with conventional therapeutic strategies for HM patients, antibody-based immunotherapies, including cancer vaccines, oncolytic virus therapies, monoclonal antibody treatments, and CAR-T cell therapies, have displayed longer survival time and fewer adverse reactions, even though specific efficacy and safety of these antibody-based immunotherapies still need to be evaluated and improved. This review summarized the advantages of antibody-based immunotherapies over conventional treatments, as well as its existing difficulties and solutions, thereby enhancing the understanding and applications of antibody-based immunotherapies in HM treatment.

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Antibody treatment'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles